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Secondary monoclonal gammopathy of undetermined signiﬁcance (MGUS) is a special phenomenon that
occurs during the treatment of multiple myeloma (MM). The incidence, biological characteristics, and
prognostic value of secondary MGUS in patients with MM remain undeﬁned. We proceed with a retrospective
systematic review of serum immunoﬁxation electrophoresis studies performed in 438 cases of patients with
plasma cell dyscrasias, including 409 cases of newly diagnosed MM and 29 cases of primary plasma cell
leukemia. Secondary MGUS was more common in patients with myeloma who had undergone stem cell
transplantation than in those who had not (17 [29.8%] of 57 versus 5 [1.4%] of 352, P < .001). The clinical
parameters and cytogenetic characteristics in patients with or without secondary MGUS were comparable.
The complete response rates in patients with or without secondary MGUS were 81.8% and 21.8% respectively
(P < .01). For the cohort as a whole, secondary MGUS was associated with signiﬁcantly prolonged
progression-free survival (median, 52.0 months versus 22.5 months; P ¼ .002) and overall survival (median,
not reached versus 35.0 months; P < .001). The presence of secondary MGUS retained independent prog-
nostic value with a moderate impact on overall survival (hazard ratio .128 [95% conﬁdence interval .018 to
.922]; P ¼ .041) in the multivariate Cox regression model. However, when analysis was restricted to patients
undergoing stem cell transplantation, no statistical differences in progression-free survival and overall sur-
vival were found. In conclusion, we observe that secondary MGUS was frequently observed in MM patients
after transplantation and conferred a survival prolongation. The favorable survival in patients with secondary
MGUS may be explained by beneﬁcial effect from myeloablative therapy.
 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION The prognostic value of secondary MGUS is still an open
Single serum monoclonal protein of constant isotype and
light-chain restriction are hallmarks of multiple myeloma
(MM). Practically, both serum and urine M-protein concen-
trations are used to stage myeloma patients and to document
responses to treatments [1]. Occasionally, some patients may
develop new monoclonal gammopathies of an isotype
(heavy and/or light chain) distinct from the original M
component after treatment, which are termed secondary
monoclonal gammopathy of undetermined signiﬁcance
(MGUS) [2,3]. The pathophysiology of secondaryMGUS is not
clear, and the incidence and clinical features of secondary
MGUS in patients with MM remain undeﬁned.dgments on page 324.
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13.11.022question. Most studies showed that the appearance of sec-
ondary MGUS was associated with prolonged survival [2,4],
whereas other studies show contradicting results [3].
Moreover, it is still unknownwhether the beneﬁcial effect of
secondary MGUS is from high depth of response or low-risk
underlying genetic features.
To address this issue, we explored the prevalence, clinical
characteristics, and prognostic signiﬁcance of secondary
MGUS in a cohort of newly diagnosed MM and primary
plasma cell leukemia (pPCL) patients. Our study demon-
strated that secondary MGUS had a beneﬁcial impact on
survival in the overall series; however, it lost prognostic
value when analysis was restricted to patients undergoing
stem cell transplantation (SCT). No clinicobiological charac-
teristics related to a favorable prognosis were found in pa-
tients with secondary MGUS. The superior outcome may be
explained by beneﬁcial effect from myeloablative therapy.
MATERIALS AND METHODS
Patients
We identiﬁed 438 cases of patients with plasma cell dyscrasias between
January 2004 and December 2012, with amedian follow-up of 3 years. TheseTransplantation. Published by Elsevier Inc. All rights reserved.
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were classiﬁed as MM and plasma cell leukemia (PCL) according to the In-
ternational Myeloma Working Group [5].
According to their request, patients were assigned to either the
thalidomide-based or bortezomib-based treatment. Thalidomide-based
treatment consisted of 4 cycles of induction treatment with (thalidomide
200 mg/day, adriamycin 9 mg/m2 administered intravenously on days 1 to 4,
and dexamethasone 20mg/day orally or intravenously on days 1 to 4 and 9 to
12; or thalidomide 200mg/day, cyclophosphamide 300mg/m2 intravenously
on days 1 and 8, and dexamethasone 20 mg/day orally or intravenously on
days 1 to 4 and 9 to 12); bortezomib-based treatment consisted of 4 cycles of
induction treatment with BCD (bortezomib 1.3 mg/m2 intravenously on days
1, 4, 8, and 11; cyclophosphamide 300 mg/m2 intravenously on days 1 and 8;
and dexamethasone 20mg/day, orally or intravenously, on days 1, 2, 4, 5, 8, 9,
11, and 12) or PAD (bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and
11; adriamycin 9 mg/m2 intravenously on days 1 to 4; and dexamethasone
20 mg/day orally or intravenously on days 1, 2, 4, 5, 8, 9, 11, and 12). After at
least 4 cycles of treatment with partial remission or better, patients under-
went consolidation therapy, which was either autologous stem cell trans-
plantation (ASCT) or chemotherapy with the patient’s original regimen
according to their request. Subsequently, patients were treated with thalid-
omide (100mg/day to 150mg/day) for 1 year tomaintain the response.When
necessary, some of them also received supportive treatment with zoledronic
acid every 1 to 2 months and erythropoietin or granulocyte colony-
stimulating factor. All patients underwent prophylactic acyclovir treatment.
Identiﬁcation of Patients with Secondary MGUS
Patients who developed a secondary MGUS were identiﬁed through a
retrospective analysis of serum immunoﬁxation electrophoresis (IFE). IFE
test was performed with Sebia Hydragel kits on the Sebia Hydrasys elec-
trophoresis system (Sebia, Norcross, GA) using agarose gels. The identiﬁ-
cation of secondary MGUS required the detection of at least 1 new
monoclonal (M) protein with heavy and/or light chain immunoglobulin
different from the initially diagnosed MM [2].
Fluorescence in Situ Hybridization
All MM samples were puriﬁed using the Miltenyi technology (Miltenyi
Biotec, Paris, France) with anti-CD138ecoated magnetic beads before ﬂuo-
rescence in situ hybridization (FISH) analysis as previously reported [6].
Plasma cells were then analyzed using DNA probes speciﬁc for the following
chromosomal aberrations: del(13q14), del(17p), t(11;14), t(4;14), and
t(14;16). Gains of 1q21 were assessed using a bacterial artiﬁcial chromo-
some probe at 1q21 (RP11-307C12) [7]. A total of 200 interphase nuclei were
analyzed. The cut-off values recommended by the European Myeloma
Network were used: for deletions and numerical aberrations, the cut-off
level was set at 20%; for translocations in the IgH locus, as well as other
translocations, the cut-off level was set at 10% [8].
Serum-free Light Chain Measurements
The serum-free light chain (FLC) concentrations were measured neph-
elometrically using Freelite automated immunoassay (Binding Site, Bir-
mingham, United Kingdom) on an IMMAGE II system (Beckman Coulter,
Krefeld, Germany). Our previous study has determined the reference range
of serum free k and l light chains in a group of Chinese patients. For the k to
l free light chain ratio (rFLC), the 95% reference interval was .27 to 1.35 [9].
Statistical Analyses
The primary end point was the correlationwith survival from the time of
diagnosis. Progression-free survival (PFS) was calculated from the initiation
of therapy to the date of death, progression, or last follow-up. Overall sur-
vival (OS) was measured from the initiation of treatment to the date of death
or last follow-up, according to the International Uniform Response Criteria
[10]. Two-sided Fisher exact tests were used to assess associations between
categorical variables, with a conﬁdence coefﬁcient of 95%. Survival curves
were plotted using the Kaplan-Meier method, with differences assessed
with the log-rank test. Results were considered signiﬁcant if the P value was
less than or equal to .05.
RESULTS
Prevalence of Secondary MGUS in Patients with Plasma
Cell Dyscrasias
Two hundred and forty patients with untreated, symp-
tomatic MM were treated with thalidomide-based therapy,
among whom 11 patients underwent ASCT. One hundred and
ﬁfty-nine myeloma patients received bortezomib-based ther-
apy and 44 of them received ASCT. Eight patients were treatedwith lenalidomide and 2 patientswere treatedwith allogeneic
bone marrow transplantation. In the PCL patients, 3 were
treated with high dose therapy (HDT)/ASCT, 2 with allogeneic
bone marrow transplantation, 20 with thalidomide-based
therapy, and 4 with bortezomib-based therapy.
A total of 26 of the 438 patients (5.9%) developed sec-
ondary MGUS. No statistical difference was found between
MM and PCL patients (22 [5.4%] of 409 for MM versus 4
[13.8%] of 29 for PCL, respectively; P ¼ .06). Secondary
MGUS was much more common in patients with myeloma
who had undergone SCT than in those who had not (17
[29.8%] of 57 patients versus 5 [1.4%] of 352, respectively;
P < .001).
In myeloma patients receiving bortezomib- or
lenalidomide-based chemotherapy, secondary MGUS was
observed in 10.9% (18 of 174) of the patients versus 1.7% (4 of
235) of those receiving thalidomide-based chemotherapy
(P < .001). In the cases of ASCT, secondary MGUS was
observed in 27.3% (3 of 11) of patients with MM receiving
thalidomide-containing regimens as induction therapy
versus 30.5% (14 of 46) of those receiving bortezomib-based
therapy before transplantation. No statistical difference was
found between these 2 groups (P¼ .29). In patients whowere
ineligible for high-dose therapy and transplantation, sec-
ondary MGUS was detected in 2.4% (3 of 123) of cases
receiving bortezomib- or lenalidomide-based therapy versus
.9% (2 of 229) of those receiving thalidomide-based chemo-
therapy. The difference between these 2 groups was not
signiﬁcant either (P ¼ .31).
Characteristics of Secondary MGUS
The main characteristics of myeloma patients who
developed secondaryMGUS are shown in Table 1. All patients
with secondary MGUS produced only 1 new monoclonal
protein. The most common oligoclonal immunoglobulin was
IgG k (69.2%), followed by IgG l (15.4%), free k (7.7%), IgM l
(3.8%), and IgA l (3.8%). The median time from diagnosis to
secondary MGUS occurrence was 9.2 months (95% conﬁ-
dence interval [CI], 2.0 to 34.8 months). Among SCT patients,
themedian time from the date of ASCT to the development of
secondary MGUS was 4.4 months (95% CI, .3 to 19.1 months).
Secondary MGUS was detected at more than 12 months after
ASCT in 9 cases (56.2%), while at less than 12 months after
ASCT in 7 cases (43.8%). The median duration of secondary
MGUS from appearance to disappearance was 4.4 months
(range, .3 to 19.1 months).
Clinical and Biological Signiﬁcance of Secondary MGUS
As shown in Table 2, there was no signiﬁcant difference
between MM patients with or without secondary MGUS in
either the median age or distributions determined by the
International Staging System stage, Durie-Salmon stage,
immunologic subtypes, and patterns of antigen expression.
As the genetic changes have emerged as the most
important prognostic factors in myeloma patients, we
examined chromosome aberrations by FISH. According to the
Intergroupe Francophone du Myelome stratiﬁcation of the
myeloma model, high-risk MM was deﬁned as the presence
of any 1 or more of the following criteria: deletion of 17p13,
or t(4;14), or t(14;16) [6].The distribution of chromosomal
aberrations was similar in both groups. It seemed that the
occurrence of secondary MGUS was associated with a lower
frequency of del(13q), and high-risk chromosome aberra-
tions were uncommon. However, these differences were not
statistically signiﬁcant.
Table 2








Age, median (range), yr 49.5 (34-66) 58 (26-83) NS
International Staging
System
I 7 of 21 (33.3) 66 of 343 (19.2) NS
II 7 of 21 (33.3) 128 of 343 (37.3) NS
III 7 of 21 (33.3) 149 of 343 (43.4) NS
Durie-Salmon stage
I 0 of 22 (0.0) 15 of 374 (4.0) NS
II 1 of 22 (4.5) 31 of 374 (8.3) NS
III 21 of 22 (95.5) 328 of 374 (87.7) NS
Best response
CR 17 of 22 (77.2) 67 of 225 (29.8) <.01
VGPR 5 of 22 (22.8) 88 of 225 (39.1) <.05
PR 0 of 22 (0%) 226 of 225 (11.6) NS
<PR 0 of 22 (0%) 44 of 225 (19.6) <.05
M component at
diagnosis
IgG 10 of 22 (45.5) 186 of 380 (49.0) NS
IgA 7 of 22 (31.8) 99 of 380 (26.0) NS
IgD 2 of 22 (9.1) 14 of 380 (3.7) NS
IgM 0 of 22 (0.0) 3 of 380 (0.8) NS
Light chain 3 of 22 (13.6) 63 of 380 (16.6) NS
Non-secretory 0 of 22 (0.0) 15 of 380 (3.9) NS
Immunophenotype
CD56 positive 13 of 17 (76.5) 184 of 291 (63.2) NS
CD117 positive 3 of 17 (17.6) 75 of 292 (25.7) NS
CD20 positive 3 of 17 (17.6) 42 of 295 (14.2) NS
Cytogenetic
abnormalities
del(13q) 5 of 17 (29.4) 124 of 266 (46.6) NS
del(17p) 1 of 17 (5.9) 28 of 265 (10.6) NS
IGH translocation 8 of 16 (50.0) 155 of 266 (58.3) NS
1q21 gains 6 of 13 (46.2) 115 of 230 (50.0) NS
t(11;14) 4 of 16 (25.0) 58 of 252 (23.0) NS
t(4;14) 2 of 16 (12.5) 56 of 246 (22.8) NS
t(14;16) 0 of 16 (0.0) 9 of 245 (3.7) NS
High-risk* 3 of 17 (17.6) 85 of 272 (31.3) NS
Ploidy
Hypodiploid 2 of 17 (11.8) 23 of 284 (8.1) NS
Diploid 15 of 17 (88.2) 253 of 284 (89.1) NS
Hyperdiploid 0 of 17 (0.0) 8 of 284 (2.8) NS
MGUS indicates monoclonal gammopathy of undetermined signiﬁcance;
ISS, International Staging System; Ig, immunoglobulin; DS, Durie Salmon;
NS, not signiﬁcant; IgA, immunoglobulin A; IgG, immunoglobulin G; IgD,
immunoglobulin D; CR, complete response; VGPR, very good partial
response; PR, partial response.
Data presented are n (%) unless otherwise indicated.











1* 65 M No free k free k/ IgG k/ normal
2 44 F No IgG l IgG l/ IgG lþIgM l/ IgG l
3 47 M Yes IgA k IgA k/ normal/ IgG k/
normal
4 58 M No IgA k free k IgA k free k/ IgG k free k/ IgA
k
5 59 F No free k free k/ normal IgG k/ normal
6* 40 F Yes IgG l free l IgG l free l/ IgG l/ IgG k
7 53 M Yes IgG l IgG l/ IgG k
8 53 F Yes IgG l IgG l/ IgG l free l/ IgG l free
k/ IgG l
9 50 M Yes free l free l/ normal/ IgG k/
normal
10 49 M Yes IgG l IgG l/ IgG k/ normal
11 45 M Yes IgA k IgA k/ IgG k/ normal
12 58 M No IgG l IgG l/ IgG lþIgG k/ IgG l
13 50 M Yes IgG l free l IgG l free l/ IgG l/ IgG k/
normal/ IgG l/ free l/ IgG k
/ free l
14 45 M Yes IgD l IgD l/ l/ IgG k free l/ IgD l
15 48 M Yes IgG l IgG l/ normal/ IgG k/
normal
16 49 M Yes IgG l free l IgG l free l/ IgG l/ IgG k
17 44 M Yes free l free l/ IgG l/ normal
18 47 M No IgG k IgG k/ IgG kþIgG l/ IgG k
19 58 M Yes IgA l IgA l/ normal/ IgG l/ IgA l
20 56 M Yes IgA k IgA k/ IgG k/ normal
21* 58 M Yes IgG k IgA k/ normal/ IgG k/ IgG
kþIgA k/ IgA k
22 35 F Yes IgA k IgA k/ normal/ IgA l free l/
normal
23 48 M Yes IgG k IgG k/ IgG l/ IgG k
24 51 M Yes IgA l IgA l/ normal/ IgG k/
normal
25 66 M No IgD l free l IgD l free l/ IgD/ IgG k
26* 44 M Yes IgG l IgG l/ normal/ IgG l/ free k
/ IgG l
MGUS indicates monoclonal gammopathy of undetermined signiﬁcance;
ASCT, autologous stem cell transplantation.
* Primary plasma cell leukemia.
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The median PFS and OS of the entire cohort with MM
were 25.0 months (95% CI, 19.9 to 30.0) and 36.0 months
(95% CI, 29.4 to 42.6), respectively. Figure 1 shows the impact
of secondary MGUS on both PFS and OS of patients with MM.
Despite the small number of patients with secondary MGUS,
these patients had a clearly better disease outcome
compared with those without secondary MGUS. The median
PFS was 52.0 months (95% CI, 41.1 to 62.9) in patients with
secondary MGUS versus 22.5 months (95% CI, 19.6 to 25.4)
for the rest of the cohort (P ¼ .002). Patients with secondary
MGUS also had much longer OS, and the median OS was not
reached versus 35.0 months (95% CI, 29.4 to 40.6) for the
patients without secondary MGUS (P < .001) (Figure 1).
Univariate analysis performed on the whole group of 409
patients identiﬁed several prognostic factors that had signiﬁ-
cant negative effect on OS. These factors included advanced
International Staging System (ISS) stage (P< .001),17pdeletion
(P < .001), 13q deletion (P ¼ .009), t(4; 14) (P ¼ .042), 1q gains
(P ¼ .006), and absence of secondary MGUS (P < .001). A
multivariate Cox regression model including ISS stage, chro-
mosome aberration determined by FISH and secondaryMGUS
was applied. The presence of secondary MGUS retained inde-
pendentprognosticvalues forOS(HR, .128 [95%CI, .018 to .922],
P¼ .041). A similaranalysis forpredictionofPFSdidnot identify
presenceof secondaryMGUSas independentprognostic factor.Prognostic Value of Secondary MGUS Receiving Different
Therapy
We then studied the impact of secondary MGUS on sur-
vival in patients newly diagnosed with MM and treated with
thalidomide-based therapy, and found that secondary MGUS
showed a tight association with superior survival. Patients
with secondary MGUS had a signiﬁcantly prolonged PFS
(93.5 months versus 20.0 months, P ¼ .002) and OS (not
reached months versus 30.0, P < .001) compared with pa-
tients without secondary MGUS (Figure 2).
In patients receiving bortezomib-based therapy, median
PFS in patients with and without secondary MGUS was 43.5
and 25.0 months, respectively (P ¼ .126), and median OS was
58.0 and 35.0 months respectively (P ¼ .029). Secondary
MGUS was associated with longer OS, but had no impact on
PFS (Figure 3).
Survival was then analyzed in patients undergoing SCT.
Patients with secondary MGUS seemed to have a longer
median PFS, but the difference was not statistically
Figure 1. Kaplan-Meier curves demonstrating PFS and OS in newly diagnosed MM patients with secondary MGUS for the cohort as a whole.
D. Zou et al. / Biol Blood Marrow Transplant 20 (2014) 319e325322signiﬁcant (52 months versus 41.0 months; P¼ .126). Median
OS was not reached in both group and no statistical differ-
ence was found (P ¼ .220) (Figure 4).
Serum FLC Measurements
Only 6 cases of the 26 patients with secondary MGUS had
qualiﬁed serum stored at -80C. The rFLC levels in these 6
patients were .887, .656, 1.481, 0.828, 1.075, and 0.995
respectively. Only 1 patient had an rFLC value higher than
1.35, indicating an increase of k free light chain over l free
light chain.
The total light chain levels were measured in 18 patients
when secondary MGUS appeared. The median levels of k
light chain and l light chain were 538.0 mg/dL (range,
1.85mg/dL to 1750.0 mg/dL) and 336.0mg/dL (range, 5.0 mg/
dL to 994.0 mg/dL), respectively. The median k to l ratio was
1.47 (range, .37 to 5.03).
DISCUSSION
Herein we report the impact of secondary MGUS in pa-
tients with plasma cell dyscrasias receiving different treat-
ments. Abnormal protein bands and oligoclonal bands have
been reported in patients undergoing myeloablative therapy
through comparative analysis with samples collected from
patients at the time of diagnosis and follow-up treatmentFigure 2. Kaplan-Meier curves demonstrating PFS and OS in newly diagnosed M[11-14]. These abnormal proteins are also termed secondary
MGUS [2,3]. Secondary MGUS is not speciﬁc to MM and has
been seen in other tumors after SCT [15]. The pathophysi-
ology of secondary MGUS is unclear, which may reﬂect a
recapitulation of early immunocyte ontogeny after
chemotherapy.
The incidence of secondary MGUS is highly variable.
However, it is widely accepted that this phenomenon is more
common in patients post SCT. In a large cohort study, a sec-
ondary MGUS was found to occur in 104 (22.7%) of 458 pa-
tients who had undergone SCT, a much higher rate compared
with those who had not undergone SCT (24 [1.6%] of 1484
patients) [3]. Consistent with previous studies, the incidence
of secondary MGUS in our study was 5.9%, which was also
higher in patients treated with bone marrow transplantation
compared with those receiving less intensive therapy (29.8%
versus 1.4%, P < .001). The incidence of secondary MGUS in
patients with plasma cell dyscrasias other than myeloma has
not previously been reported. In our study, 4 of the 29 pPCL
(13.8%) patients developed secondary MGUS, and the inci-
dence of secondaryMGUSwas comparable betweenMM and
pPCL.
It has been reported that the secondary MGUS incidence
was different in patients achieving complete remission after
conventional cytotoxic therapy compared with patientsM patients with secondary MGUS in thalidomide-based treatment group.
Figure 3. Kaplan-Meier curves demonstrating PFS and OS in newly diagnosed MM patients with secondary MGUS in bortezomib-based treatment group
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ported that 33% of patients treated with clarithromycin,
lenalidomide, and dexamethasone developed what they
termed atypical serum IFE patterns [4]. For the cohort as a
whole, we also detected a higher incidence of secondary
MGUS in MM patients after initial treatments with borte-
zomib or lenalidomide compared with those treated with
thalidomide-based therapy. However, in our series, most
patients (44 of 55) undergoing SCT received bortezomib-
based therapy as induction treatment before ASCT. There-
fore, the discrepancy of secondary MGUS incidences might
be a result of SCT. When analysis was performed in the
transplantation group, no statistical difference was found
between the 2 groups. Similar results were obtained when
analysis was restricted to patients who were ineligible for
high-dose therapy and transplantation. Therefore, the
occurrence of secondary MGUS is likely due to the high-dose
myeloablative chemotherapy rather than the effect of novel
agents.
The prognostic signiﬁcance of secondary MGUS remains
controversial, mainly because this situation does not occur
frequently. Most of the studies have been focused on patients
undergoing transplantation. In a multivariate analysis of 471
of 550 post-transplantation MM patients, abnormal protein
bands was discovered to be a favorable factor for bothFigure 4. Kaplan-Meier curves demonstrating the impact of secondary MGUS on PFSevent-free survival and OS [14]. Recently, a Spanish group
also found that the presence of oligoclonality resulted in a
signiﬁcantly longer PFS and OS [17]. However, when Manson
et al. assessed the status of secondary MGUS, they could not
ﬁnd a signiﬁcant association between secondary MGUS and
good prognosis [3]. In a large retrospective cohort study
conducted by Mayo Clinic, OS was clearly superior among
patients who developed secondary MGUS compared with
the rest of the cohort. But among MM patients who under-
went SCT, the OS was not signiﬁcantly different in the group
who developed a secondary MGUS compared with other
patients [2]. Our results demonstrated a prognostic signiﬁ-
cance of secondary MGUS similar to the report by Mayo
Clinic. In the overall series, patients with secondary MGUS
had a much longer OS and PFS than the rest of the cohort. In
multivariable analysis, secondary MGUS was still an inde-
pendent prognostic factor for OS, but the impact on OS was
moderate. Parameters that had the most profound impact on
survival were genetic features and advanced ISS stage.
In the current series, when the analysis was restricted to
patients undergoing SCT, no statistical signiﬁcance was
found between patients with or without secondary MGUS. It
should also be noted that most of the patients with sec-
ondary MGUS were from the group of SCT in current study,
and the favorable outcome in patients with secondary MGUSand OS in newly diagnosed MM patients undergoing stem cell transplantation.
D. Zou et al. / Biol Blood Marrow Transplant 20 (2014) 319e325324may derive from more intensive transplantation therapies.
Although the role of high-dose therapy followed by ASCT in
the treatment of MM has been challenged when novel agents
have been used, myeloablative therapy is still irreplaceable
considering the beneﬁcial effect of secondary MGUS.
Another possibility was that the sample size of patients with
secondary MGUS in the transplantation setting was not
enough to reach statistical signiﬁcance when the analysis
was restricted to patients undergoing SCT. The result needs
to be conﬁrmed using larger patient cohorts.
As mentioned above, secondary MGUS was associated
with a superior outcome. We examined whether the good
prognosis associated with secondary MGUS resulted from
favorable clinical characteristics or low-risk underlying ge-
netic features. Consistent with a recent study [11], in our
series, patients with or without secondary MGUS were
similar with respect to age, ISS stage, Durie-Salmon stage,
immunologic subtypes, and immunophenotype at diagnosis.
We further demonstrated that the molecular cytogenetic
aberrations were also not statistically different between the
groups of patients with or without secondary MGUS. Thus, a
different outcome could not be expected on the basis of these
markers.
Of note, in our study, secondary MGUS was associated
with a signiﬁcantly higher rate of complete response (CR)
(81.8% versus 21.8%, P < .001). Many studies have indicated
that the quality of response, especially achievement of CR or
at least very good partial response, is a prognostic factor for
improved long-term outcomes [18]. The better survival of
patients with secondary MGUS may result from their higher
depth of response compared with other patients. Thus, the
development of secondary MGUS appears to be a surrogate
marker of the reduction in malignant plasma cells as evi-
denced by the high proportion of achievement of CR. The
exact magnitude of response in patients with secondary
MGUS should be assessed using currently available sensitive
techniques, such as multiparameter ﬂow cytometry, real-
time PCR.
The International Myeloma Working Group has intro-
duced the concept of stringent CR deﬁned by a normal bone
marrow (as determined by immunocytochemistry or
immunoﬂuorescence) plus a normal serum free-light chain
kappa-lambda ratio [19]. A recently published study showed
that the presence of oligoclonal bands in MM patients with
CR frequently resulted in an abnormal rFLC. In their study,
the frequency of abnormal FLC ratios in patients with or
without oligoclonal bands was 72.7% versus 26%, respectively
(P ¼ .023) [20]. However, our study showed contradicting
results: only 1 of 6 patients with secondary MGUS had an
abnormal rFLC in our study, which was consistent with the
results by Alejandre et al. [21]. As only a small number of
patients with secondary MGUS had qualiﬁed serum to
measure rFLC, the result needs to be conﬁrmed using larger
patient cohorts.
In summary, our result indicates that secondary MGUS is
frequently observed in MM patients after transplantation,
and is associated with a more favorable prognosis. The
clinical parameters and cytogenetic characteristics in pa-
tients with or without secondary MGUS are comparable. The
favorable survival could be explained by the higher depth of
response, especially after myeloablative therapy.
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